Vietnam Device Inspections: Unlicensed Sale and Overpricing Fines

Updated: 2026-11-05 · GRZAN Regulatory Team · Verification date 2026-10-20

Q: What do Vietnamese inspections focus on?

A: Inspections usually run along four lines:

  1. Product access — whether there is a circulation number, a Declaration of Applicable Standards or an import licence (Article 22(a) of Decree 98);
  2. Labelling and instructions — whether labels meet Decree 37/2026 (including a font size of at least 0.9 mm, the date format and device-specific items), and whether Vietnamese instructions for use and warranty information are present (Article 22(b), (c) and (d));
  3. Company qualifications — whether Class B/C/D traders have completed the Trading Eligibility Declaration and whether staff and warehousing continue to meet Article 40;
  4. Price and advertising — whether price declaration is complete, whether sales exceed the published price, and whether advertising is published on the portal and consistent with the declaration (Article 62).

Q: What happens to unlicensed circulation?

A: It is a serious violation of the circulation conditions. Article 22 makes holding a circulation number or an import licence the first condition of circulation, so without one there is no lawful basis to circulate. Consequences include an order to stop circulation, batch suspension, recall and administrative action. From 1 July 2025, the transitional arrangement allowing import and sale on a classification document has ended, and such conduct no longer has any policy cushion.

Q: What happens with sales above the published price?

A: Decree 98 expressly prohibits “trading devices without a declared price” and “trading at prices above those published on the MOH website“. This is a quantifiable and verifiable violation: comparing the portal price with the transaction records establishes it, the evidential burden is low, and it is therefore high-risk in inspections.

Q: What are the penalties for advertising violations?

A: Article 54 of Decree 38/2021/NĐ-CP (on administrative penalties in cultural and advertising activities, as amended) sets the penalties for device advertising violations. Read with Article 62, the most common problems are advertising content inconsistent with the declared scope (claiming undeclared indications or effects) and publishing without prior publication on the portal.

Q: Who carries out inspections?

A: At product level, the MOH/IMDA and the provincial Departments of Health divide the work: post-licensing inspection, batch suspension and recall for Class C/D are handled by IMDA, while Class A/B declarations and trading eligibility are received and supervised by the provincial Department of Health. Decree 04/2025 also confirms that the MOH may inspect and revoke an import licence in the event of a violation.

Practical note: run an annual compliance health check against the four lines, keeping a dated self-assessment record for each. The point is not “is there a violation” but “can compliance be evidenced“: portal publication screenshots, the Trading Eligibility Declaration publication, price declaration receipts, advertising publication receipts and adverse event records. In an inspection, being able to produce evidence and being in fact compliant are two different things.

Verification checklist (26 October 2026): (1) Decree No. 98/2021/NĐ-CP, Article 22 (the four circulation conditions); (2) Decree No. 98/2021/NĐ-CP, Article 62 (advertising) and Article 75.3; (3) Decree No. 38/2021/NĐ-CP (29 March 2021), Article 54; (4) Decree No. 37/2026/NĐ-CP (23 January 2026, labelling); (5) Decree No. 04/2025/NĐ-CP (MOH inspection and revocation of import licences); (6) Decree 98/2021/NĐ-CP price provisions.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail